Literature DB >> 23507742

Targeted therapies: One step closer to drugging p53.

Mina Razzak.   

Abstract

Entities:  

Year:  2013        PMID： 23507742     DOI： 10.1038/nrclinonc.2013.43

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours.

Authors:  M A Warso; J M Richards; D Mehta; K Christov; C Schaeffer; L Rae Bressler; T Yamada; D Majumdar; S A Kennedy; C W Beattie; T K Das Gupta
Journal:  Br J Cancer       Date:  2013-02-28       Impact factor: 7.640
  1 in total
  3 in total

1.  A Method of Tumor In Vivo Imaging with a New Peptide-Based Fluorescent Probe.

Authors:  Samer Naffouje; Masahide Goto; Ingeun Ryoo; Albert Green; Tapas K Das Gupta; Tohru Yamada
Journal:  Methods Mol Biol       Date:  2022

2.  Improved Classification of Lung Cancer Using Radial Basis Function Neural Network with Affine Transforms of Voss Representation.

Authors:  Emmanuel Adetiba; Oludayo O Olugbara
Journal:  PLoS One       Date:  2015-12-01       Impact factor: 3.240

3.  Tumor-targeting cell-penetrating peptide, p28, for glioblastoma imaging and therapy.

Authors:  Sunam Mander; Samer A Naffouje; Jin Gao; Weiguo Li; Konstantin Christov; Albert Green; Ernesto R Bongarzone; Tapas K Das Gupta; Tohru Yamada
Journal:  Front Oncol       Date:  2022-07-22       Impact factor: 5.738
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.